- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Primary Malignant Central Nervous System Neoplasm, Locally Advanced Sarcoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Primary Malignant Central Nervous System Neoplasm, Metastatic Sarcoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Avapritinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1537–1560
of 2,209
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Melanoma, Skin Cancer
- Interventions
- Ipilimumab, Nivolumab, Cryoablation
- Drug · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- NSCLC, Renal Cell Carcinoma, Breast Carcinoma, Melanoma, Brain Metastases, Adult, Non-small Cell Lung Cancer, SCLC, Small-cell Lung Cancer
- Interventions
- single fraction stereotactic radiosurgery (SSRS), fractionated stereotactic radiosurgery (FSRS)
- Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 34
- States / cities
- Savannah, Georgia • Decatur, Illinois • Effingham, Illinois + 26 more
- Conditions
- Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS)
- Interventions
- Burosumab
- Biological
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 7
- States / cities
- Golden, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 4 more
- Conditions
- Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Malignant Neoplasm, Leukemia, Lymphoma, Malignant Solid Neoplasm, Sarcoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Thyroid Gland Carcinoma
- Interventions
- Internet Mobile Technology, Internet-Based Intervention, Questionnaire Administration, Supportive Care, Informational Intervention
- Other · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Rhabdomyosarcoma, Melanoma
- Interventions
- Tc99m tilmanocept, Vital Blue Dye (optional), Lymph Node Mapping
- Drug · Procedure
- Lead sponsor
- Cardinal Health 414, LLC
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Orlando, Florida • Cincinnati, Ohio + 3 more
- Conditions
- Melanoma, Advanced Melanoma
- Interventions
- Biopsy, Biospecimen Collection
- Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Melanoma
- Interventions
- Skin Self Examination Information and ABCDE Rule
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Maywood, Illinois • Lebanon, New Hampshire
- Conditions
- Melanoma (Skin)
- Interventions
- oblimersen sodium, dacarbazine
- Biological · Drug
- Lead sponsor
- Genta Incorporated
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Berkeley Heights, New Jersey
- Conditions
- Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
- Interventions
- Trastuzumab deruxtecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more
- Conditions
- Melanoma
- Interventions
- Pembrolizumab, Nivolumab, Indoximod
- Drug
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 4
- States / cities
- Iowa City, Iowa • Rochester, Minnesota • Albuquerque, New Mexico + 1 more
- Conditions
- Melanoma
- Interventions
- ZK-EPO
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Melanoma
- Interventions
- dendritic cell vaccine
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Unresected Stage IIIb to IVM1c Melanoma
- Interventions
- Talimogene Laherparepvec
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Melanoma
- Interventions
- Cyclophosphamide, Fludarabine, Interleukin-2, TIL Product
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
- Interventions
- Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
- Drug · Radiation
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Tumors, Malignant Melanoma, Hematological Malignancies, Myelogenous Leukemia, Chronic, Leukemia, Lymphoblastic, Acute
- Interventions
- Immunoablative Hematopoietic PBSC Transplant, Busulfan pharmacokinetics, Central Nervous System (CNS) prophylaxis radiation
- Procedure · Radiation
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers
- Interventions
- IFx-Hu2.0
- Biological
- Lead sponsor
- TuHURA Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 1 more
- Conditions
- CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Any T-cell Malignancy, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma, Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Burkett's Lymphoma, Primary Lymphoma of the Central Nervous System
- Interventions
- CDX-1127
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more
- Conditions
- Basal Cell Carcinoma, Squamous Cell Carcinoma
- Interventions
- electronic brachytherapy
- Radiation
- Lead sponsor
- Xoft, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 5
- States / cities
- Tuscaloosa, Alabama • Casa Grande, Arizona • Scottsdale, Arizona + 2 more
- Conditions
- Metastatic Melanoma, Skin Cancer
- Interventions
- cyclophosphamide, fludarabine phosphate, Aldesleukin, ALVAC gp100 Vaccine, anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Solid Tumors
- Interventions
- 1-methyl-D-tryptophan
- Drug
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Melanoma
- Interventions
- Vemurafenib
- Drug
- Lead sponsor
- Philip Friedlander
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Interventions
- aldesleukin, ipilimumab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- CINJRegulatory
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 6
- States / cities
- Maywood, Illinois • Boston, Massachusetts • New Brunswick, New Jersey + 3 more